TheraRadar
Clinical-Stage Companies / Ascentage Pharma Group

Ascentage Pharma Group

Pre-Approval PRO BETA
42
Total Trials
7
Phase 3
13
Phase 2
25
Recruiting
315
Score

Pipeline by Phase

Phase 3
7
Phase 2
13
Phase 1
32

Therapeutic Focus

Chronic Lymphocytic Leukemia Advanced Solid Tumor CLL/SLL Solid Tumor, Adult Small Lymphocytic Lymphoma

Clinical Trials (42)

NCT06389292 Phase 3 RECRUITING

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Started: 6/11/2024

NCT06641414 Phase 3 RECRUITING

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Started: 1/22/2025

NCT06104566 Phase 3 RECRUITING

Global Trial in APG2575 for Patients With CLL/SLL

Started: 12/20/2023

NCT06423911 Phase 3 RECRUITING

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Started: 2/5/2024

NCT06640361 Phase 3 RECRUITING

A Study of Olverembatinib in SDH-deficient GIST.

Started: 11/11/2024

NCT06051409 Phase 3 RECRUITING

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Started: 8/31/2023

NCT06319456 Phase 3 RECRUITING

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Started: 4/7/2024

NCT05147467 Phase 2 RECRUITING

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Started: 12/28/2021

NCT04496349 Phase 2 RECRUITING

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Started: 7/12/2021

NCT04126681 Phase 2 COMPLETED

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Started: 10/21/2019

NCT05773586 Phase 1 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

Started: 3/13/2023

NCT03594422 Phase 1 RECRUITING

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Started: 7/11/2018

NCT07282093 Phase 1 RECRUITING

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

Started: 11/11/2025

NCT06182969 Phase 1 RECRUITING

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Started: 8/9/2024

NCT04260022 Phase 1 RECRUITING

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Started: 1/9/2020

NCT04501120 Phase 1 RECRUITING

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Started: 9/28/2020

NCT03917043 Phase 1 RECRUITING

APG-2449 in Patients With Advanced Solid Tumors

Started: 5/27/2019

NCT04494503 Phase 1 RECRUITING

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Started: 8/31/2020

NCT04215809 Phase 1 RECRUITING

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Started: 3/2/2020

NCT04785196 Phase 1 RECRUITING

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Started: 5/26/2021

NCT06687070 Phase 1 RECRUITING

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Started: 12/17/2024

NCT05701306 Phase 1 RECRUITING

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Started: 2/28/2023

NCT04275518 Phase 1 RECRUITING

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Started: 7/6/2020

NCT07424833 Phase 1 NOT YET RECRUITING

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Started: 3/1/2026

NCT04643405 Phase 1 TERMINATED

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Started: 3/17/2021

NCT04284488 Phase 1 TERMINATED

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Started: 4/10/2020

NCT04001777 Phase 1 ACTIVE NOT RECRUITING

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Started: 7/4/2019

NCT04260217 Phase 1 COMPLETED

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Started: 5/30/2021

NCT03611868 Phase 1 ACTIVE NOT RECRUITING

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Started: 8/29/2018

NCT04893759 Phase 1 TERMINATED

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Started: 1/6/2022

NCT03913949 Phase 1 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Started: 6/3/2019

NCT04946864 Phase 1 SUSPENDED

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Started: 8/13/2021

NCT05517616 Phase 1 COMPLETED

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

Started: 9/14/2022

NCT03386526 Phase 1 COMPLETED

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Started: 11/21/2017

NCT04354727 Phase 1 WITHDRAWN

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Started: 12/15/2020

NCT04210037 Phase 1 TERMINATED

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Started: 8/20/2020

NCT02935907 Phase 1 COMPLETED

APG-115 in Patients With Advanced Solid Tumors or Lymphomas

Started: 10/1/2016

NCT03080311 Phase 1 COMPLETED

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Started: 2/12/2017

NCT03585322 Phase 1 COMPLETED

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Started: 7/4/2018

NCT04126707 Phase 1 COMPLETED

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Started: 11/19/2019

NCT03387332 Phase 1 TERMINATED

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Started: 12/1/2017

NCT03882281 Phase 1 COMPLETED

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

Started: 3/25/2019

Drug Candidates

APG-5918 Placebo HQP1351 APG2575 APG-3288 APG-1387 for Injection Gemcitabine Nab paclitaxel Toripalimab Olverembatinib 20mg
Activity Status: Active
Last Trial Started: 3/1/2026
Last Trial Ended: 8/13/2025
Trials (12 months): 2
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.